ICICI Securities research report on Nestle India
Our assertion / hypothesis: Nestlé’s infant nutrition business (~30% of revenues and ~40% of profits) will likely face growth headwinds in CY2021 due to consumers (now) delaying plans of having infants / babies due to fear of visiting hospitals. Given the premium pricing of infant nutrition products, the consuming households are mostly the upper-middle class / middle class, in our view. We have drawn conclusions from (1) our primary research with pharmaceutical companies and (2) secondary sales data (market research) from AIOCD-AWACS (MUST see charts 1-3).
Though we are believers in Nestlé’s long-term story, our current neutral stance is intact (given that only a part of its portfolio (Maggi and (somewhat) Coffee) would benefit from increased in-home consumption). HOLD rating retained.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.